Drug
CLR1404 clinical trials
Also written CLR 131, I-131-CLR1404 and iopofosine I 131.
Keep track of what changes. Save the CLR1404 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Cellectar Biosciences, Inc. (7) · University of Wisconsin, Madison (1) · Cellectar, Inc (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses CLR1404 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsNot yet recruitingPhase 3Cellectar Biosciences, Inc.NCT07766421Written as Iopofosine I 131
- Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGActive, not recruitingPhase 1Cellectar Biosciences, Inc.NCT05610891Written as CLR 131
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingPhase 1Cellectar Biosciences, Inc.NCT03478462Written as CLR 131
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingPhase 2Cellectar Biosciences, Inc.NCT02952508Written as Iopofosine I 131 single dose
- CLR 131 Combined With Radiation for Head and Neck CancerCompletedPhase 1University of Wisconsin, MadisonNCT04105543Written as CLR 131
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1Cellectar Biosciences, Inc.NCT02278315Written as I-131-CLR1404
- Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has ReturnedCompletedPhase 1Cellectar Biosciences, Inc.NCT01495663Written as I-131-CLR1404
- Open-Label Study of I-131-CLR1404 in Subjects With Recurrent GliomaWithdrawnPhase 2Cellectar Biosciences, Inc.NCT01778088Written as I-131-CLR1404 Injection
- Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid TumorsCompletedPhase 1Cellectar, IncNCT00925275Written as I-131-CLR1404
As the comparator · 1 — what is tested is compared with CLR1404
Codes
What other systems call CLR1404 · ClinicalTrials.gg INT000262
- MeSH (NLM) C000599353CLR1404One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599353 | CLR1404 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.